Vulvovaginal Candidiasis (Candida albicans)

Overview


Plain-Language Overview

Vulvovaginal Candidiasis (Candida albicans) is a common infection affecting the vaginal area and surrounding tissues in women. It is caused by an overgrowth of the yeast Candida albicans, which normally lives in small amounts in the vagina without causing harm. When this yeast grows excessively, it leads to symptoms such as itching, burning, and a thick, white vaginal discharge. The infection primarily affects the female reproductive system and can cause significant discomfort. It is not considered a sexually transmitted infection but can be influenced by factors like antibiotics, diabetes, or hormonal changes. The condition is usually localized but can recur frequently in some women.

Clinical Definition

Vulvovaginal Candidiasis (VVC) is an inflammatory condition of the vulva and vagina caused by the overgrowth of the yeast Candida albicans. This yeast is part of the normal vaginal flora but can become pathogenic when the local immune defenses or vaginal microbiome are disrupted. The core pathology involves fungal invasion of the vaginal mucosa, leading to inflammation, erythema, and pruritus. VVC is characterized by a thick, curd-like vaginal discharge and vulvar irritation. It is a major cause of vaginitis and can significantly impair quality of life due to recurrent episodes. Predisposing factors include antibiotic use, immunosuppression, diabetes mellitus, and pregnancy. Diagnosis and management focus on identifying the yeast and differentiating it from other causes of vaginitis.

Inciting Event

  • Recent broad-spectrum antibiotic therapy is a common trigger for fungal overgrowth.

  • Hormonal fluctuations such as those during pregnancy or menstrual cycle can initiate infection.

  • Uncontrolled hyperglycemia in diabetes precipitates fungal proliferation.

  • Use of intravaginal products or irritants can disrupt mucosal barriers facilitating infection.

Latency Period

  • Symptoms typically develop within days to 1 week after the inciting event or trigger.

  • Fungal colonization may precede symptoms by several days before clinical infection manifests.

Diagnostic Delay

  • Symptom overlap with bacterial vaginosis or trichomoniasis often leads to misdiagnosis.

  • Empiric treatment without confirmatory testing delays accurate diagnosis and targeted therapy.

  • Failure to recognize recurrent or complicated cases can prolong time to diagnosis.

Clinical Presentation


Signs & Symptoms

  • Vulvar pruritus is the hallmark symptom.

  • Burning sensation and irritation of the vulva and vagina.

  • Thick, white, odorless vaginal discharge described as cottage cheese-like.

  • Dyspareunia and dysuria may occur due to mucosal inflammation.

  • Erythema and edema of the vulva and vaginal mucosa are common on exam.

History of Present Illness

  • Onset of intense vulvar pruritus and burning often precedes other symptoms.

  • Thick, white, curd-like vaginal discharge is characteristic and typically odorless.

  • Dysuria and dyspareunia commonly develop as infection progresses.

  • Symptoms often worsen during or after menses due to hormonal changes.

Past Medical History

  • Previous episodes of vulvovaginal candidiasis increase risk of recurrence.

  • History of diabetes mellitus is a significant predisposing factor.

  • Recent antibiotic or corticosteroid use is frequently reported.

  • Immunosuppressive conditions or therapies contribute to susceptibility.

Family History

  • No strong familial inheritance pattern is associated with vulvovaginal candidiasis.

  • Rare genetic defects in innate immunity (e.g., CARD9 deficiency) may predispose to recurrent infections.

Physical Exam Findings

  • Erythematous and edematous vulvar and vaginal mucosa with possible excoriations from scratching.

  • Thick, white, curd-like vaginal discharge adherent to the vaginal walls.

  • Absence of malodor helps differentiate from bacterial vaginosis.

  • Vulvar erythema and fissures may be present in severe cases.

  • Normal or mildly increased vaginal pH (typically <4.5) distinguishes it from other infections.

Diagnostic Workup


Diagnostic Criteria

Diagnosis of vulvovaginal candidiasis is established by clinical presentation of vulvar itching, erythema, and characteristic thick white vaginal discharge. Microscopic examination of vaginal discharge using a wet mount or KOH preparation reveals budding yeast or pseudohyphae, which is confirmatory. Culture of vaginal secretions can be used if microscopy is inconclusive or in recurrent cases. The absence of bacterial pathogens and negative tests for other causes of vaginitis help exclude differential diagnoses. Diagnosis relies on the combination of typical symptoms and direct visualization of Candida organisms.

Pathophysiology


Key Mechanisms

  • Overgrowth of Candida albicans disrupts normal vaginal flora leading to infection.

  • Adherence of fungal hyphae to vaginal epithelial cells triggers local inflammation.

  • Host immune response involves neutrophil recruitment causing mucosal irritation and symptoms.

  • Altered vaginal pH favors fungal proliferation and virulence factor expression.

  • Biofilm formation by Candida enhances resistance to antifungal agents and persistence.

InvolvementDetails
Organs

Vagina is the main organ affected, where Candida albicans overgrowth causes symptoms of vulvovaginal candidiasis

Vulva is involved in the clinical presentation with erythema, edema, and pruritus due to local fungal infection

Tissues

Vaginal mucosa is the primary site of infection and inflammation in vulvovaginal candidiasis

Epidermis of the vulva is involved in local immune defense and can show erythema and irritation during infection

Cells

Neutrophils are recruited to the site of infection and mediate fungal clearance through phagocytosis and release of reactive oxygen species

Epithelial cells of the vaginal mucosa provide a physical barrier and produce antimicrobial peptides against Candida albicans

Macrophages contribute to fungal clearance by phagocytosis and cytokine production to coordinate immune response

Chemical Mediators

Interleukin-17 (IL-17) is a key cytokine promoting neutrophil recruitment and antifungal defense in vulvovaginal candidiasis

Tumor necrosis factor-alpha (TNF-α) enhances inflammatory response and helps control fungal infection

Defensins are antimicrobial peptides secreted by epithelial cells that disrupt fungal cell membranes

Treatments


Pharmacological Treatments

  • Fluconazole

    • Mechanism:
      • Inhibits fungal cytochrome P450 enzyme 14-alpha-demethylase, disrupting ergosterol synthesis and fungal cell membrane integrity

    • Side effects:
      • Hepatotoxicity

      • Gastrointestinal upset

      • Headache

    • Clinical role:
      • First-line

  • Clotrimazole

    • Mechanism:
      • Inhibits ergosterol synthesis by blocking 14-alpha-demethylase, leading to increased fungal cell membrane permeability

    • Side effects:
      • Local irritation

      • Burning sensation

      • Allergic reaction

    • Clinical role:
      • First-line

  • Miconazole

    • Mechanism:
      • Disrupts fungal cell membrane by inhibiting ergosterol synthesis via 14-alpha-demethylase inhibition

    • Side effects:
      • Local irritation

      • Pruritus

      • Burning

    • Clinical role:
      • First-line

  • Nystatin

    • Mechanism:
      • Binds to ergosterol in fungal cell membranes, creating pores that cause ion leakage and cell death

    • Side effects:
      • Local irritation

      • Contact dermatitis

    • Clinical role:
      • Second-line

Non-pharmacological Treatments

  • Maintain good genital hygiene with gentle cleansing and avoid irritants such as scented soaps or douches

  • Wear loose-fitting, breathable cotton underwear to reduce moisture and fungal growth

  • Manage underlying risk factors such as diabetes mellitus and immunosuppression to prevent recurrence

Prevention


Pharmacological Prevention

  • Prophylactic antifungal therapy with topical azoles in recurrent cases.

  • Use of fluconazole maintenance therapy for frequent relapses.

  • Avoidance of broad-spectrum antibiotics unless necessary to reduce fungal overgrowth.

Non-pharmacological Prevention

  • Maintaining good genital hygiene and keeping the area dry.

  • Avoiding tight-fitting synthetic clothing to reduce moisture retention.

  • Managing underlying diabetes mellitus with good glycemic control.

  • Avoiding irritants such as scented soaps, douches, and spermicides.

  • Using cotton underwear to promote ventilation and reduce fungal growth.

Outcome & Complications


Complications

  • Recurrent vulvovaginal candidiasis causing chronic symptoms.

  • Secondary bacterial infection from excoriations and mucosal breakdown.

  • Vulvar cellulitis in severe untreated cases.

  • Psychological distress due to chronic pruritus and discomfort.

Short-term Sequelae Long-term Sequelae
  • Acute vulvar inflammation with erythema and edema.

  • Discomfort during urination and intercourse due to mucosal irritation.

  • Increased vaginal discharge causing hygiene issues and social distress.

  • Chronic vulvovaginal candidiasis with persistent symptoms despite treatment.

  • Lichenification and skin changes from repeated scratching.

  • Psychosexual dysfunction due to ongoing pain and discomfort.

Differential Diagnoses


Vulvovaginal Candidiasis (Candida albicans) versus Bacterial Vaginosis

Vulvovaginal Candidiasis (Candida albicans)

Bacterial Vaginosis

Overgrowth of yeast, primarily Candida albicans

Overgrowth of anaerobic bacteria such as Gardnerella vaginalis

Thick, white, curd-like discharge without strong odor

Thin, grayish-white discharge with fishy odor

Pseudohyphae and budding yeast on KOH prep

Clue cells on wet mount

Improves with azole antifungals such as fluconazole

Improves with metronidazole or clindamycin

Vulvovaginal Candidiasis (Candida albicans) versus Trichomoniasis

Vulvovaginal Candidiasis (Candida albicans)

Trichomoniasis

Fungal infection with Candida albicans

Infection with motile protozoan Trichomonas vaginalis

Thick, white, curd-like discharge

Frothy, yellow-green vaginal discharge

Pseudohyphae and budding yeast on KOH prep

Motile trichomonads on wet mount

Prominent vulvar pruritus and irritation without strong odor

Often associated with vaginal itching and malodor

Vulvovaginal Candidiasis (Candida albicans) versus Atrophic Vaginitis

Vulvovaginal Candidiasis (Candida albicans)

Atrophic Vaginitis

Premenopausal or reproductive-age women

Postmenopausal women due to estrogen deficiency

Thick, white, curd-like discharge

Thin, pale vaginal mucosa with scant discharge

Severe vulvar itching and burning

Vaginal dryness and dyspareunia without intense pruritus

Improves with antifungal agents

Improves with topical estrogen therapy

Vulvovaginal Candidiasis (Candida albicans) versus Contact Dermatitis

Vulvovaginal Candidiasis (Candida albicans)

Contact Dermatitis

No specific irritant exposure; fungal overgrowth

Recent exposure to irritants or allergens such as soaps or hygiene products

Pruritus with thick white discharge and vulvar erythema

Pruritus with erythema and possible vesicles or scaling

Improves with antifungal therapy

Improves with removal of irritant and topical corticosteroids

Vulvovaginal Candidiasis (Candida albicans) versus Herpes Simplex Virus Infection

Vulvovaginal Candidiasis (Candida albicans)

Herpes Simplex Virus Infection

Erythema and white curd-like vaginal discharge without vesicles

Painful vesicles and ulcers on vulva

Intense vulvar itching and burning without systemic symptoms

Severe pain and dysuria with systemic symptoms possible

Positive KOH prep showing pseudohyphae and budding yeast

Positive PCR or viral culture for HSV

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.